A Faster, But More Procedurally Complex, BA/BE Landscape
India’s bioavailability/bioequivalence (BA/BE) study framework has undergone its most significant procedural overhaul in years, and the changes are still rippling through CRO operations and sponsor timelines as of October 2026. For companies relying on Indian BA/BE centres to generate data for generic drug filings — whether for the domestic market or for overseas regulated markets — understanding the new pathway, and the paperwork gaps that have emerged around it, is now essential to avoid costly delays.
The Prior Intimation Pathway: Rule 52 Comes Alive
CDSCO proposed the system in January 2026 as part of an amendment to the New Drugs and Clinical Trial Rules, 2019, designed to allow companies to start some bioavailability and bioequivalence studies after notifying authorities of their plans, rather than applying and waiting for permission to initiate the assessments. The amendment was notified as GSR 50(E), the CDSCO prior intimation pathway (CT-05), introduced under the NDCT Rules amendment dated 21 January 2026, and one of the most impactful changes under the Clinical Trials Amendment Rules 2026 is the introduction of a prior intimation pathway under Rule 52.
How It Works in Practice
Companies can now use Form CT-05 in the Sugam portal to indicate their intent to run studies under the simplified process, and the process is open to single-dose, two-period, two-sequence, two-treatment BA/BE studies of oral dosage forms in healthy adult volunteers. Under this pathway, certain BA/BE studies can be initiated through prior intimation to CDSCO instead of undergoing the standard approval process, and only the acknowledgement from CDSCO on the prior intimation is required for initiation of the eligible study.
Eligibility Criteria Sponsors Must Verify
- The standard BA/BE study design must be single dose, two period, two sequence, two treatment, conducted in healthy adult volunteers with a sample size greater than 18.
- The study must be intended for export purposes, using oral dosage forms approved with the same formulation and strength.
- The drug must be approved in India or in at least one major regulated market — the USA, EU, Japan, Australia, Canada, or UK.
Studies falling outside these parameters — modified-release forms, parenterals, inhalation products, liposomal formulations, or studies requiring steady-state/multiple-dose designs — remain subject to the conventional CT-04/CT-06 approval route and full CDSCO review.
The Import Bottleneck: Form CT-16 and the NSWS Gap
While the Prior Intimation pathway accelerates study start-up, it has exposed a separate operational problem: importing the actual Reference Listed Drug (RLD) or Investigational Medicinal Product (IMP) needed to run the study. Stakeholders had raised concerns regarding the non-availability of system linkage between Prior Intimation applications submitted through Form CT-05 on the Sugam portal and the corresponding Form CT-16 applications filed for import permissions.
In response, considering the operational difficulties faced by applicants and following the implementation of notification GSR 50(E) dated April 21, 2026, CDSCO introduced an interim procedural arrangement that will remain in force until further orders, communicated via a formal notice. In the notice dated May 22, 2026, the BA/BE for Export Division under the Directorate General of Health Services, Ministry of Health and Family Welfare, acknowledged the system disconnect between the two portals.
Documents Required for Standalone Form CT-16 Applications
Applicants intending to import RLD/IMP for the conduct of BA/BE studies for export purpose must submit a standalone Form CT-16 application through the NSWS portal along with a set of supporting documents. Based on the interim procedure, this includes:
- A covering letter explaining the purpose of import and referencing the Prior Intimation application details;
- A copy of the acknowledged Prior Intimation (Form CT-05) generated through the Sugam Portal;
- Complete details of the proposed RLD/IMP to be imported;
- A copy of the protocol or synopsis with reference details, wherever applicable; and
- Challan evidencing payment of the requisite fee as prescribed under Schedule VI of the NDCT Rules, 2019.
Importantly, submission of a standalone Form CT-16 application under this notice is treated only as an interim procedural arrangement and does not exempt applicants from compliance with the NDCT Rules, 2019 and other applicable regulatory requirements. On a positive note, the notice also directed all concerned CDSCO Zonal and Sub-Zonal Offices to process such applications on a priority basis until further orders.
Study Centre Eligibility: A Moving Target
Sponsors should also verify that their chosen BA/BE centre and bioanalytical laboratory remain currently registered. CDSCO refreshed its official List of Registered BA-BE Study Centres & Bio-Analytical Laboratories under the NDCT Rules, 2019 on 18 September 2026 — a reminder that registrations carry five-year validity periods and centres can drop off the list upon expiry or non-renewal. Using an unregistered or lapsed facility, even inadvertently, can invalidate an entire BA/BE dataset and derail a generic filing timeline by months.
Practical Takeaways for Sponsors and CROs
1. Map Your Study Against the New Criteria First
Before filing, confirm whether your proposed study genuinely qualifies for the Prior Intimation route (single-dose, 2×2 crossover, oral, export-purpose, ≥18 healthy subjects, reference approved in India or a major regulated market). Misclassifying a study can trigger rejection or forced resubmission under the standard pathway.
2. Sequence Your CT-05 and CT-16 Filings Carefully
Because the Sugam (CT-05) and NSWS (CT-16) systems are not yet technically linked, do not assume automatic recognition between the two. Obtain your acknowledged CT-05 first, then file the standalone CT-16 with all cross-referencing documents attached manually.
3. Budget for Schedule VI Fees and Keep Challans Organised
Import approvals require fee payment per Schedule VI of the NDCT Rules, 2019. Incomplete or mismatched challans are among the most common reasons for processing delays at Zonal offices.
4. Re-verify Centre Registration Status Before Every New Study
Cross-check your BA/BE centre and bioanalytical lab against the latest CDSCO list (last updated September 2026) rather than relying on older registration certificates.
5. Maintain Retention and Documentation Discipline
Keep protocol, synopsis, and reference-drug documentation audit-ready, since CDSCO Zonal offices are processing these interim CT-16 applications on a case-by-case priority basis, and incomplete submissions risk losing that priority status.
What This Means Going Forward
The Prior Intimation pathway represents a genuine shift toward faster generic development timelines in India, aligning CDSCO’s approach more closely with globally harmonised standards. But until the Sugam-NSWS linkage issue is permanently resolved, sponsors and CROs must treat the current interim arrangement as exactly that — interim — and build in buffer time and meticulous documentation to avoid processing delays at the import stage.
ACPL’s regulatory experts can help you navigate BA/BE study approvals in India. Contact us at info@acplgroupindia.co.in or call +91-9266665201 for a consultation.